Collections
Bibliography
Subscribe and Share
Links
Wednesday, April 01, 2015

DIDA - New Search Features and Countdown to Site Launch

We are excited to announce the launch of an updated version of our newly redesigned Industry Documents Digital Library (IDDL) application!

This updated release includes a new look as well as new content pages and new features.  This release also starts the countdown to the retirement of the current LTDL/DIDA sites in June 2015 so if you have not begun using the beta site, now is the time!

*Just a reminder: You can search across industry archives (LTDL and DIDA) from the main IDDL portal - http://industrydocuments.library.ucsf.edu/ or head right to the specific industry -
Tobacco = http://industrydocuments.library.ucsf.edu/tobacco OR
Drug = http://industrydocuments.library.ucsf.edu/drug

New Content Pages:
Each industry archive now has its own set of Collection, Research Tools and Help pages.  Here you will find resources such as collection descriptions for each industry archive, links to the publications/papers written using documents, fields you can use in your search and citation information.

New Search/Browse Features:
When you do a search and select a document to view, you will now notice a Browse option in the upper right of the screen.



  • "More Like This" - brings back 10 documents that match the primary document's title and author. Click on one to view it full size in the document viewer. You can always return to your original document by clicking "Back to Original" in the carousel header or just scrolling back to your highlighted original document. We hope this will assist users in finding more relevant documents and facilitate new threads of search.
  • "Prev/Next Bates" -  Allows you to view the thumbnails of documents that have bates numbers before and after the primary document.  Click on one to view it full size in the document viewer.  You can always get back to your original document by clicking "Back to Original" in the carousel header or just scrolling back to your highlighted original document.





    New "Actions" menu: 
    This menu houses all actions for the document in question: Save the record to your "Bookmark" area, download the PDF and associated attachments,  download the citation information, view all metadata in the record, and email the document to yourself and/or others.




      Please let us know how these new features are working or not working for you.  You can submit feedback through either the survey link at the top of the screen or the Ask Us form under Help.   We are confident users will find the new site has all that LTDL and DIDA had and so much more but your input will assist us in making it even better.
      Tuesday, March 10, 2015

      New Seroquel Documents posted to DIDA

      110 new documents have been added to the Seroquel collection on the Drug Industry Documents Archive (DIDA).  This collection now contains 351 documents from litigation against UK-based AstraZeneca Pharmaceuticals, the maker of Seroquel, an antipsychotic medication used to treat schizophrenia and bipolar disorder. The plaintiffs alleged the drugmaker failed to warn users of the drug's possibly harmful side effects, including the risk of diabetes and related medical complications.
      Tuesday, January 27, 2015

      New Celexa Collection posted

      The Drug Industry Documents Archive has a new collection:
      The Celexa and Lexapro Marketing and Sales Litigation collection contains 115 documents from a class action lawsuit alleging that Forest Pharmaceuticals misled consumers and the medical community about Celexa’s and Lexapro’s efficacy in treating pediatric depression.

      *Please note the links now go to the new Industry Documents Digital Library site containing both LTDL and DIDA.
      Friday, November 07, 2014

      New DIDA site is now in beta!

      For the past year we have been developing a new DIDA with expanded functionality and an updated look.  This new DIDA is now accessible alongside a new Legacy Tobacco Documents Library (LTDL) and both are found within the Industry Documents Digital Library portal.  This means all industry archives can now be searched individually or together under one umbrella.

      There are two ways to access the DIDA beta site -

      1)  Direct URL - http://industrydocuments.library.ucsf.edu/drug/
      2)  From the current DIDA site, there is a link to beta in the top banner as well as a pop up invitation that will appear.

      You might want to start by watching the tutorial, also accessible from the Tutorial Videos link at the bottom of each page. 
       
      While we are in beta, we hope as many users as possible will try out the new site, play around with the search functionality and new features, and provide feedback through the survey link located at the top of every page.  We need to know what you like and dislike about the new site in order to make it even better!
      Monday, August 18, 2014

      Zyprexa Documents and Tamiflu CSRs Added

      Zyprexa - The documents in this collection are a portion of those produced in a class action court case that alleged Eli Lilly withheld data on adverse effects such as weight gain and diabetes and participated in off-label marketing of the drug. The documents were first obtained and made public in 2006 by PsychRights.org, expert consultant Dr. David Egilman, attorney Jim Gottstein, and journalists Philip Dawdy and Alex Berenson. After a legal battle over public access, the documents were un-sealed and allowed to remain in the public domain. These documents highlight Lilly's marketing strategy of influencing key opinion leaders and its attempts to control the research, the scientific literature and regulatory product labeling to minimize information on adverse effects.

      Cochrane study on neuraminidase inhibitors – These are very large, clinical study reports that were used by the authors of “Regulatory information on trials of oseltamivir (Tamiflu) and zanamivir (Relenza) for influenza in adults and children.” A thank you to Peter Doshi at the University of Maryland School of Pharmacy for donating these documents to DIDA. We hope to add another batch of these CSRs releated to Relenza before the year is out.

      Please note, we are working hard on major revisions to DIDA to make searching, retrieving and saving documents much easier.  The new release is anticipated at the end of September and we urge you to try out the new site and give us lots of feedback.  
      Thursday, March 20, 2014

      New Clinical Study Reports Posted

      A new collection of documents, Cochrane Review: neuraminidase inhibitors, has been added to the Drug Industry Documents Archive (DIDA).  The documents in this collection are a sampling of  clinical study reports (CSRs) provided by the company Roche to a Cochrane review group conducting a systematic review of neuraminidase inhibitors (anti-influenza drugs) including oseltamivir (Tamiflu). These CSRs are comprehensive, integrated summaries of trials submitted by study sponsors to regulatory bodies in support of marketing applications. The detail in CSRs is evident in their length: approximately 100 times the page length of journal publications of trials.

      For more information see the full description under "Investigations" at Cochrane Review: neuraminidase inhibitors 

      Thursday, October 03, 2013

      Symposium on Institutional Corruption and Big Pharma


      The Fall 2013 issue of The Journal of Law, Medicine & Ethics is devoted to a special topic: Institutional Corruption and the Pharmaceutical Industry. 

      In this symposium issue, 16 articles investigate the corruption of pharmaceutical policy, each taking a different look at the sources of corruption, how it occurs, and what is corrupted. The authors show that Big Pharma's funding of election campaigns and lobbying skews the legislative process that sets pharmaceutical policy and that certain practices have corrupted medical research, the production of medical knowledge, the practice of medicine, drug safety, the Food and Drug Administration's oversight of the pharmaceutical market, and the trustworthiness of patient advocacy organizations.


      Special issue: SYMPOSIUM: Institutional corruption and the pharmaceutical industry.(2013). The Journal of Law, Medicine & Ethics, 41(3).